Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
August 2022
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
not assigned
|
| gptkbp:brand |
gptkb:Zynteglo
|
| gptkbp:cost |
approximately $2.8 million per treatment (US, 2022)
|
| gptkbp:developer |
gptkb:bluebird_bio
|
| gptkbp:EMAAuthorizationDate |
May 2019
|
| https://www.w3.org/2000/01/rdf-schema#label |
betibeglogene autotemcel
|
| gptkbp:indication |
patients with transfusion-dependent beta thalassemia
|
| gptkbp:mechanismOfAction |
inserts functional copies of the beta-globin gene into hematopoietic stem cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:synonym |
gptkb:LentiGlobin_BB305
|
| gptkbp:type |
autologous hematopoietic stem cell gene therapy
|
| gptkbp:usedFor |
beta thalassemia
|
| gptkbp:bfsParent |
gptkb:Zynteglo
|
| gptkbp:bfsLayer |
6
|